Individual (Sole proprietorship)
2013
21 - 50
Rs. 0.5 to 2.5 Crore Approx.



Amisulpride API manufactured by Swapnroop Drugs & Pharmaceuticals is a high-purity active pharmaceutical ingredient (API) used primarily in the treatment of various mental health conditions, particularly schizophrenia and acute psychotic episodes. Key Details: Therapeutic Class: Atypical antipsychotic Mechanism of Action: Acts as a selective dopamine D₂/D₃ receptor antagonist, helping to restore the balance of neurotransmitters in the brain. Form: High-quality, bulk API (Active Pharmaceutical Ingredient) suitable for formulation into tablets or injectable medications. Certifications: WHO-GMP Certified ISO Certified Manufacturing Facility Use Cases: Schizophrenia (positive and negative symptoms) Dysthymia and other depressive disorders (off-label in some regions) Swapnroop’s API ensures consistency, regulatory compliance, and is suitable for export to regulated markets globally. Would you like a product brochure or detailed technical specification sheet (TDS/MSDS) for this API? What is Amisulpride API Manufactured by Swapnroop Drugs and Pharmaceuticals used for? Therapeutic Applications of Amisulpride API Manufactured by Swapnroop Drugs & Pharmaceuticals (WHO-GMP & ISO 9001:2015 Certified) Amisulpride API is a selective dopamine D2/D3 receptor antagonist classified as an atypical antipsychotic . It is primarily used to treat psychiatric disorders due to its unique limbic system specificity. Below are its key therapeutic uses, supported by clinical and regulatory data: 1. Approved Indications A. Schizophrenia Target Symptoms : Positive Symptoms : Hallucinations, delusions, thought disorders. Negative Symptoms : Social withdrawal, emotional blunting, anhedonia. Dosage Range : 400–800 mg/day (split doses for doses >400 mg). Low doses (50–300 mg/day) preferentially improve negative symptoms. B. Acute Psychotic Episodes Rapid Action : Reduces agitation and aggression within 3–7 days . IM Formulation : Used in hospital settings for acute control. 2. Off-Label Uses (Clinically Supported) A. Dysthymia & Depression Mechanism : Dopamine modulation in mesolimbic pathways. Dose : 50 mg/day (significantly lower than antipsychotic doses).


Share your thoughts with other customers for Swapnroop Drugs & Pharmaceuticals
Add Review